El Raziky, M <br/><br/>
Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.  [electronic resource] 

 -  Journal of viral hepatitis  02 2017 
 - 102-110 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2893 
<br/><br/><label>Standard No.: </label>10.1111/jvh.12625  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Animals<br/>Antiviral Agents--administration & dosage<br/>Female<br/>Genotype<br/>Hepacivirus--classification<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Liver Cirrhosis--drug therapy<br/>Male<br/>Middle Aged<br/>Simeprevir--administration & dosage<br/>Sofosbuvir--administration & dosage<br/>Treatment Outcome<br/>Young Adult